

CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:

50-720/S-009

APPROVAL LETTER

NOV 19 1999

- NDA 50-564/S-037
- NDA 50-575/S-028
- NDA 50-597/S-033
- NDA ~~50-720/S-019~~
- NDA 50-726/S-007
- NDA 50-725/S-007
- NDA 50-590/S-037
- NDA 50-658/S-007

SmithKline Beecham Pharmaceutical
 Attention: Ms. Sharon Maglennon
 Assistant Director,
 Regulatory Affairs, North America
 1250 S. Collegeville Road
 P.O. Box 5089
 Collegeville, PA 19426-0989

Dear Ms. Maglennon:

Please refer to your supplemental new drug applications dated July 26, 1999, received July 26, 1999, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Augmentin® (amoxicillin/clavulanate potassium) Tablets, NDA 50-564; Augmentin® (amoxicillin/clavulanate potassium) 4:1 Powder for Oral Suspension, NDA 50-575; Augmentin® (amoxicillin/clavulanate potassium) Chewable Tablets, NDA 50-597; Augmentin® (amoxicillin/clavulanate potassium) BID Tablets, NDA 50-720; Augmentin® (amoxicillin/clavulanate potassium) BID Chewable Tablets, NDA 50-726; Augmentin® (amoxicillin/clavulanate potassium) 7:1 Powder for BID Oral Suspension, 50-725; Timentin® (sterile ticarcillin disodium and clavulanate potassium), NDA 50-590; Timentin® (sterile ticarcillin disodium and clavulanate potassium) for Injection in Plastic Container, PL 2040, NDA 50-658. We note that these applications are subject to the exemption provisions contained in section 125(d)(2) of Title I of the FDA Modernization Act of 1997.

These supplemental new drug applications provide for three changes to the extraction process



We have completed the review of these supplemental applications and they are approved.

NDA 50-564/S-037
NDA 50-575/S-028
NDA 50-597/S-033
NDA 50-720/S-009
NDA 50-726/S-007
NDA 50-725/S-007
NDA 50-590/S-037
NDA 50-658/S-007

Page 2


We remind you of your commitment to place in your long-term stability program, the first commercial batch (es) of drug substance. In addition, please commit the first commercial batch of drug product manufactured from the drug substance with the new process into your long-term stability program and report the stability data in your annual report, as it becomes available.

In addition, update the proposed changes in your drug master files affected.

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

If you have any questions, call CDR. Jose R. Cintron, USPHS, Senior Regulatory Management Officer/Project Manager, at (301) 827-2125.

Sincerely,



David B. Katague, Ph.D. /
Chemistry Team Leader for the
Division of Anti-Infective Drug Products,
(HFD-520)
DNDC III, Office of New Drug Chemistry
Center for Drug Evaluation and Research

**APPEARS THIS WAY
ON ORIGINAL**